Share Name Share Symbol Market Type Share ISIN Share Description
Tristel Plc LSE:TSTL London Ordinary Share GB00B07RVT99 ORD 1P
  Price Change % Change Share Price Shares Traded Last Trade
  -25.00 -4.95% 480.00 128,938 16:35:28
Bid Price Offer Price High Price Low Price Open Price
480.00 500.00 505.00 487.00 505.00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 31.68 6.64 11.38 42.2 223
Last Trade Time Trade Type Trade Size Trade Price Currency
16:35:28 O 1 500.00 GBX

Tristel (TSTL) Latest News

Tristel News

Date Time Source Headline
09/11/202009:49UKREGTristel PLC Exercise of Options
02/11/202010:30RNSNONTristel PLC Q&A update following preliminary results
27/10/202016:50UKREGTristel PLC Issue of Equity
19/10/202014:15UKREGTristel PLC Dividend Timetable
19/10/202010:16ALNCTristel's Hospital Surface Disinfection Focus Helps It Weather Virus
19/10/202006:00UKREGTristel PLC Final Results
06/10/202006:00UKREGTristel PLC Notice of Results
05/10/202015:41UKREGTristel PLC Issue of Equity
02/10/202008:11UKREGTristel PLC Issue of Equity
07/9/202012:16UKREGTristel PLC Issue of Equity
More Tristel News
Tristel Investors    Tristel Takeover Rumours

Tristel (TSTL) Discussions and Chat

Tristel Forums and Chat

Date Time Title Posts
25/11/202016:32The TRISTEL story2,960
14/9/201813:56MRSA cleaner249
15/7/201512:01Tristel PLC: Cleaning up the sector340
03/1/201004:54tristel with charts-
13/2/200607:10TSTL with Charts & News3

Add a New Thread

Tristel (TSTL) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2020-11-25 18:02:16500.0015.00O
2020-11-25 18:02:16500.00210.00O
2020-11-25 17:15:00495.0027,180134,541.00O
2020-11-25 16:35:28480.001,5107,248.00UT
2020-11-25 16:21:56487.001,9709,593.90O
View all Tristel trades in real-time

Tristel (TSTL) Top Chat Posts

Tristel Daily Update: Tristel Plc is listed in the Health Care Equipment & Services sector of the London Stock Exchange with ticker TSTL. The last closing price for Tristel was 505p.
Tristel Plc has a 4 week average price of 487p and a 12 week average price of 410p.
The 1 year high share price is 535p while the 1 year low share price is currently 280p.
There are currently 46,476,008 shares in issue and the average daily traded volume is 50,836 shares. The market capitalisation of Tristel Plc is £223,084,838.40.
zimbtrader: Perhaps more towards luck than deliberate timing! Have done this a lot with TSTL and always feel quite sad when I sell them and a bit nervous when I rebuy. I suspect a chance will come in the next few months sub 450.
james188: I also take the view that ongoing reevaluation of the pros and cons of a share is necessary, particularly when seismic events - such as those we are experiencing at the moment - occur. New products will inevitably appear over time, but it will be a relatively long haul before they are approved by the main regulatory authorities. Look at what TSTL are going through in the US with the FDA for products that have been widely approved in numerous other jurisdictions. After that, health authorities and other consumers have to be persuaded to switch from products that have been heavily scrutinised and approved. Surely it would be easier for one of the bigger players to simply acquire TSTL. That has to be the most likely endgame. The US is not the be-all and end-all, but it is one of the most obvious jurisdictions from which a buyer may emerge. I wonder if that is one of the main reasons that TSTL has decided to really ramp up its approval programmes with both the FDA and the EPA. It is not that long ago - less than twelve months,I believe - that TSTL scaled back the number of products in its FDA programme. At that point, the focus was all about Duo for ultrasound devices. Based on the final results and the supporting presentation earlier this week, it now appears that the US programme is receiving a big push, with a substantially increased supporting budget. Interesting times.
mighunter: Piedro, a 2 second search of your post history shows you posting on TSTL as early as 2008 - if not before. Why you ask the basic questions you initially have, when the answers have been freely available to seek in those intervening 12 years, I do not know. So what credible information do you actually possess, leading you to suggest that other companies could already be in the process of adopting similar technology.... and further, what proof do you have of it being maybe in a year. And why now rather than any other point in your 12 year history posting on TSTL, as your argument certainly hasn't come true in that timeframe. If you're going to suggest such speculative hunches, it'll need a better explanation you stating that the dinosaurs are now extinct.
james188: The share price movements on this share are always interesting - and often somewhat puzzling. Anyone who read the TSTL Q&A would have known that TSTL expected to be in a position to start selling product into India in the current financial year, so the approvals announced today are very welcome, but hardly a surprise. I agree with the earlier observation that too much focus has been made about the US opportunity (when there are lots of other markets to go for). That said, the US focus was on high level disinfectants for medical devices - and specifically for ultrasound product (Duo). Again the Q&A responses indicate that TSTL is now looking hard at the surface cleaning and disinfection market in the US, where EPA approval is sufficient. No doubt they would need a new distribution partner other than Parker, but it is an obvious market opportunity and there was virtually no share price reaction. I am still adding.
paulisi: Positive news - hopefully, they can get a sales team set up and ready to drive some revenue.Share price should jump on this and US approval when it comes.
james188: On the subject of share based payments, the concern is understandable and I thought that Phil Oakley made some valid points in the IC webcast today. That said, I personally don't have problem with senior management being rewarded well for growing the company significantly year on year and generating excellent shareholder total returns. I first remember this issue coming to the fore for TSTL in early 2016, when the share price was around 110p.The complaint was that the 2015 LTIP was incorrectly calibrated and led to windfall gains. It had been 96p when the scheme was documented. A revised scheme (the 2018 LTIP) was announced in November 2017 and set out in some detail at that time - options granted to senior management vested if the share price achieved 350p, 425p and 500p for a minimum three month period.There was a considerable amount of adverse comment at the time, but for all that, I was the only external shareholder who turned up for the 2017 AGM and asked the company about the arrangements. Responses were provided by David Orr (head of the Remuneration Committee) and Geoff Nash (company broker). I have not located my detailed notes, but I recall that I was told that a detailed comparison had been carried out with other bio companies - many of which were still loss making, unlike TSTL. The conclusion was that the proposed TSTL arrangements were fully in line and not towards the top end. You can make the argument (as certain well known and respected commentators certainly have) that the product sells itself, irrespective of the quality of management. I do not share that view. I think that the company is at a potential inflection point and that senior management needs to be laser focused.The SBP are certainly an issue, but not the central one for me.
james188: The director sales were largely to fund exercise/tax costs.I don't have an issue with that and I am much more interested in the long term trend of the share price and the company's prospects. I continue to believe that the company is still at a fairly early stage in its evolution. There are a lot of further opportunities that should be relatively easy to convert, both geographically and in product range.The fact that management is cautious is a plus point for me, but I hope (and expect)that they seize the present opportunities. I have lots of questions (which I have set out today in an e-mail to the company),but I saw today as an obvious buy opportunity. The share price has always been volatile and I don't suppose that that will change within the foreseeable future.
melody9999: Well having read the TU, I did not see that coming. Not sure how positive the update needed to be to avoid a fall in the share price Sure I understand the company's cautious note due to uncertainty - but I think we have a double benefit now with pent up demand from hospital operations combined with increased emphasis on cleaning meaning TSTL products will be in great demand. Added.
james188: I have been topping up materially of late. TSTL has never been really cheap and I first invested relatively late in September 2005, having tracked it for just over 12 months. I should have got in much earlier. I take the view that TSTL is still at an early stage in its journey. The UK NHS market is obviously very important, but TSTL now sells most of its product outside the UK. It has lots of new markets where it has hardly started - even if you forget the US opportunity (which I don't).China, India and South America and others all spring to mind. I also expect (and hope) that it will get involved in the consumer market, most probably with a major partner in order to deliver at scale. The COVID virus has boosted the share price, but much less than some other COVID related stocks. To me, it is blindingly obvious that products that zap the ever increasing bugs that we are having to confront will be in demand. Other virus strains will doubtless appear over the next few months and years. This is an obvious roll out.
metis20: Piedro - "At Tristel the exertion seems minimal, repeating the old formula and letting the momentum carry them forward." What evidence do you have for this?! Did you attend a recent Investor Presentation? The impression I obtained at the late afternoon session was of a decidedly hard working and innovative duo leading the company. Https:// Share holder approval was of course required. Vesting conditions - that was when the share price was £2.75 · One-third will vest upon the achievement of a share price of £3.50; · One-third will vest upon the achievement of a share price of £4.25; · One-third will vest upon the achievement of a share price of £5.00. Between 4 August 2015 and 1 November 2017, the Company's share price has increased from 96 pence to 275 pence, and the Company's market capitalisation has increased from £40 million to £118 million. The Board considers that the 2015 Scheme has successfully met its objectives.
Tristel share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20201126 02:14:17